SCHEMBL5145698

SCHEMBL5145698

O=C(Nc1cccnc1)C(=Cc1ccc(C(F)(F)F)nc1)C(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
CSF1R P07333 4/20 0.49
KIT P10721 1/20 0.49
KDR P35968 1/20 0.49
MAPK14 Q16539 1/20 0.49
BRAF P15056 1/20 0.48
KIF11 P52732 1/20 0.48
RXFP1 Q9HBX9 1/20 0.46
EPHX2 P34913 1/20 0.45
NAMPT P43490 2/20 0.45
GAA P10253 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145694 1.00 TSHR (0.53) TSHRKMT2AMEN1CSF1RKIT
SCHEMBL5142373 0.93 ERBB2 (0.49) TSHRKMT2AMEN1GAANPSR1
SCHEMBL5144564 0.86 SMARCA2 (0.48) TSHRKMT2AMEN1ALOX15NPSR1
SCHEMBL5144568 0.86 SMARCA2 (0.48) TSHRKMT2AMEN1ALOX15NPSR1
SCHEMBL5141400 0.86 AURKA (0.47) TSHRKMT2AMEN1
SCHEMBL5141399 0.86 AURKA (0.47) TSHRKMT2AMEN1
SCHEMBL5144544 0.86 BRAF (0.49) TSHRKMT2AMEN1CSF1RKIT
SCHEMBL5144541 0.86 BRAF (0.49) TSHRKMT2AMEN1CSF1RKIT
SCHEMBL5142698 0.81 KMT2A (0.52) TSHRKMT2AMEN1CSF1RKIT
SCHEMBL5142700 0.81 KMT2A (0.52) TSHRKMT2AMEN1CSF1RKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2007-02-22 US claimed
WO-2005037196-A2 SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA, INC. (US) 2005-04-28 WO claimed
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CYTOVIA, INC. 2007-02-22 US disclosed
WO-2005037196-A2 SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS CYTOVIA, INC. (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043076-A1 Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis CASP14, CASP2, CASP3 TSHR 3821/4885KMT2A 1674/4885MEN1 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.